Tumor-associated macrophages (TAMs) are frequently observed at the invasive front of patient tumors, often in conjunction with cancer cells that have undergone epithelial-mesenchymal transition (EMT). This correlation between TAMs and EMTmodified cancer cells suggests a close interaction between these 2 cell populations. We recently reported that EMT-altered breast cancer cells have a superior ability to activate macrophages to an M2 phenotype as compared to their malignant counterparts that have not undergone EMT. 1 Mesenchymallike breast carcinoma cells stimulate macrophages via the production of high levels of granulocyte-macrophage colony-stimulating factor (GM-CSF, also known as CSF-2). Reciprocally, chemokine [C-C motif] ligand 18 (CCL18) from TAMs induces EMT of cancer cells. Furthermore, GM-CSF from cancer cells and CCL18 from TAMs form a positive feedback loop to maintain the EMT and M2-macrophage activation status in co-culture systems and humanized mice. Neutralization of either GM-CSF or CCL18 breaks this vicious cycle and reduces breast cancer metastasis in vitro or in vivo.
1 This study has also demonstrated a number of key points that we shall discuss further below.
EMT and Remissive Microenvironment Fostering are
Linked by NFkB Signaling By exploring the mechanism by which cancer cells that undergone EMT massively produce GM-CSF, we have identified nuclear factor kB (NFkB) as a crucial link between malignant cell mobility and their ability to foster a remissive microenvironment for cancer cells. 1 The chemokine CCL18 induces NFkB activation via PITPNM3/Pyk2/Src/PI3K/Akt pathway that stabilizes and upregulates Snail (Snai1), a transcription factor underlying EMT. On the other hand, NFkB upregulates a panel of inflammatory cytokines, including GM-CSF that induces TAMs to adopt an immunosuppressive M2 phenotype (Fig. 1) .
Humanized Mouse Models: Bridging Rodent Models to Human Tumor Microvironment
Various positive feedback loops between cancer cells and macrophages have been identified in mouse models, including the macrophage colony stimulating factor (Csf-1, also known as M-CSF) and epidermal growth factor (EGF) paracrine loop. 2 However, the chemokine profiles of immune cells are species specific, 3 and many chemokines upregulated in human M2 macrophages are either absent or not upregulated in mice. 4 CCL18, a key metastasis promoting and TAM-derived cytokine in humans, 5 does not have a mouse counterpart. Therefore, we adopted a humanized mouse model by engrafting irradiated and severely immunodeficient mice with CD34 C haematopoietic stem cells (HSCs) 3 to bridge the gap between rodent models and patient disease by mimicking the human breast tumor microenvironment. We have reported that neutralizing antibodies that break the vicious cycle between GM-CSF and CCL18 abrogate lung and liver metastasis in these mice. 1 These findings are consistent with previous reports that depletion of macrophages by M-CSF knockout in breast cancer susceptible polyoma middle T (PyMT) mice abolished lung metastasis, without altering carcinogenesis and primary tumor growth.
2 Therefore, TAMs preferentially affect breast cancer metastatic spread. 
Cancer Cells Autonomously
Produce GM-CSF
Our study is consistent with previous reports that cancer cells can autonomously produce high amounts of GM-CSF, a potent cytokine that promotes the progression of various malignancies. For example, in a variety of experimental tumors, cancer cell derived GM-CSF rapidly induces the generation of myeloidderived suppressor cells (MDSCs) and tumor immunosuppression in mice. 6 Human disease relevancy has been validated in a clinical trial in which a subset of MDSCs were expanded in metastatic melanoma patients administered GM-CSF-based vaccines. 7 Interestingly, GM-CSF has been reported to be among the most potent immune adjuvants for administering tumor vaccines. However, clinically, GM-CSF efficacy as a tumor vaccine adjuvant is controversial. Some studies have demonstrated that GM-CSF enhances antitumor immune responses, whereas others have shown no effect, or even an adverse outcome. 8 Our data, and those of others, clearly demonstrate the potential for opposing effects of GM-CSF via activating macrophages in various malignancies.
The GM-CSF Signaling Context Decodes the TAM Response
It has been suggested that the existence of concomitant stimulatory factors contribute to the dichotomy of GM-CSF effects in inflammatory tissues. Indeed, we have observed that GM-CSF alone can induce the production of both pro-inflammatory and anti-inflammatory cytokines. 1 In the presence of lactate, which is abundant in the tumor microenvironment, GM-CSF-activated macrophages cannot produce proinflammatory cytokines, but rather, generate vast quantities of anti-inflammatory cytokines. It is widely accepted that cancer cells produce excessive lactate even under normoxic conditions, a phenomenon termed the Warburg Effect, or aerobic glycolysis. Such high levels of lactate facilitate GM-CSF stimulated TAMs to undergo M2 polarization, highlighting the link between cancer metabolism and tumor-related inflammation. Indeed, recent studies indicate lactate may contribute to cancer cell immune evasion. For example, lactate impairs differentiation of monocytes to dendritic cells and production of pro-inflammatory cytokine by cytotoxic T cells, but does not affect the function of regulatory T cells. 9 Therefore, the selective effects of lactate on different immune cell subsets foster an immunosuppressive microenvironment for cancer progression and its underlying mechanism warrants further investigations.
An increasing number of drugs have been developed to tackle cancer metabolism by targeting key enzymes. Many glycolysis inhibitors re-sensitize cancer cells to chemotherapy and radiotherapy. 10 In support, we have observed that blocking lactate production by pretreating MDA-MB-231 cells with oxamic acid, an inhibitor of lactate dehydrogenase, skewed the polarization of macrophages stimulated by tumorderived GM-CSF to a pro-inflammatory phenotype. 1 Collectively, our results link tumor metabolism with (Fig. 1) .
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